Abstract
Neurological complications including pain are common after treatment for breast cancer. This prospective study investigated the symptoms, intensity and interference of chemotherapy-induced peripheral neuro-pathy. (CIPN) in the feet and hands compared to surgery-and radiation-induced neuropathy in the breast and upper arm. Consecutive patients referred to surgery for breast cancer were included in a prospective study and completed a questionnaire at baseline and a follow-up questionnaire and interview after one year. CIPN was assessed with the CIPN20 questionnaire and the Michigan Neuropathy Screening Instrument questionnaire (MNSIq). Pain intensity was rated on a numeric rating scale (NRS, 0-10). In total 144 patients were included, of which 73 received chemotherapy. At one-year follow-up, symptoms of polyneuropathy were more common in patients treated with chemotherapy. Tingling or numbness in the feet in those treated/not treated with chemotherapy was reported by 44 (62%) and 15 (21%), respectively. Pain was present in 22 (30%) and 10 (14%), respectively. Pain in the area of surgery was reported by 66 (46%). Although less common, pain in the feet in those treated with chemotherapy was rated as more intense and with more daily life interference than pain in the surgical area (NRS 5.5 (SD 1.9) vs. 3.1 (SD 1.9). Neurological complications including pain following surgery and chemotherapy represent a burden to breast cancer survivors. In those who had received chemotherapy, pain in the feet was less common than pain in the surgical area, but pain in the feet was more intense and had a higher interference with daily life. Our study emphasizes the need for either baseline data or a control population for improved estimation of the presence and severity of CIPN and pain from questionnaires.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Scandinavian Journal of Pain |
| Vol/bind | 23 |
| Udgave nummer | 1 |
| Sider (fra-til) | 49-58 |
| ISSN | 1877-8860 |
| DOI | |
| Status | Udgivet - 27. jan. 2023 |
Bibliografisk note
Funding Information:Research funding: This work was supported by the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement No 633491 (DOLORisk). The funding source had no involvement in the conduct of the study, manuscript preparation, or decision to publish.
Funding Information:
Competing interests: The authors declare no conflict of interest. Outside the submitted work, DB has acted as consultant for Grünenthal, Novartis, Bayer, Air Liquide, Vertex, and Angelini. Outside the submitted work, DLB has acted as a consultant on behalf of Oxford Innovation for Amgen, Bristows, LatigoBio, GSK, Ionis, Lilly, Olipass, Orion, Regeneron and Theranexus over the last 2 years. He has received research funding from Lilly and has received an industrial partnership grant from the BBSRC and AstraZeneca outside the submitted work. NA has received honoraria from Pfizer, Grunenthal, Novartis, Upsa, Merz Pharma, Air Liquide, and Biogen outside the submitted work. NBF reports personal fees from Almirall, NeuroPN, Novartis Pharma, and Vertex and has undertaken consultancy work for Aarhus University with remunerated work for Biogen, Merz, and Confo Therapeutics, outside the submitted work and has received a grant from IMI2PainCare an EU IMI 2 (Innovative Medicines Initiative) public-private consortium and the companies involved are: Grünenthal, Bayer, Eli Lilly, Esteve, and Teva, outside the submitted work.
Finansiering
Research funding: This work was supported by the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement No 633491 (DOLORisk). The funding source had no involvement in the conduct of the study, manuscript preparation, or decision to publish. Competing interests: The authors declare no conflict of interest. Outside the submitted work, DB has acted as consultant for Grünenthal, Novartis, Bayer, Air Liquide, Vertex, and Angelini. Outside the submitted work, DLB has acted as a consultant on behalf of Oxford Innovation for Amgen, Bristows, LatigoBio, GSK, Ionis, Lilly, Olipass, Orion, Regeneron and Theranexus over the last 2 years. He has received research funding from Lilly and has received an industrial partnership grant from the BBSRC and AstraZeneca outside the submitted work. NA has received honoraria from Pfizer, Grunenthal, Novartis, Upsa, Merz Pharma, Air Liquide, and Biogen outside the submitted work. NBF reports personal fees from Almirall, NeuroPN, Novartis Pharma, and Vertex and has undertaken consultancy work for Aarhus University with remunerated work for Biogen, Merz, and Confo Therapeutics, outside the submitted work and has received a grant from IMI2PainCare an EU IMI 2 (Innovative Medicines Initiative) public-private consortium and the companies involved are: Grünenthal, Bayer, Eli Lilly, Esteve, and Teva, outside the submitted work.
Fingeraftryk
Dyk ned i forskningsemnerne om 'Neuropathy and pain after breast cancer treatment: A prospective observational study'. Sammen danner de et unikt fingeraftryk.Citationsformater
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver